Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: Results of a prospective randomized phase III study

Cancer

Volumn 83, Issue 2, 1998, Pages 291-301

  Kern, Wolfgang ^a   Behre, Gerhard ^a   Rudolf, Thomas ^a   Kerkhoff, Andrea ^b   Grote Metke, Albert ^c   Eimermacher, Hartmut ^d   Kubica, Ursula ^e   Wörmann, Bernhard ^a   Büchner, Thomas ^b   Hiddemann, Wolfgang ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c EVANGELISCHES KRANKENHAUS   (Germany)

^d Katholisches Krankenhaus Hagen   (Germany)

^e Children's Hospital   (Germany)

Author keywords

Acute myeloid leukemia; Fluconazole; Fungal infections; Prophylaxis

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIFUNGAL ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; FEMALE; FLUCONAZOLE; HUMANS; IMMUNOCOMPROMISED HOST; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYCOSES; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; SALVAGE THERAPY;

EID: 0032527958     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980715)83:2<291::AID-CNCR13>3.0.CO;2-O     Document Type: Article

References (46)

1. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis 1995;21:361-9.
2. DeGregorio MW, Lee WMF, Linker CA, Jacobs RA, Ries CA. Fungal infections in patients with acute leukemia. Am J Med 1982;73:543-8.
3. Donhuisen K, Samandari S. Tiefe mykosen in patienten mit leukämien und lymphomen. Dtsch Med Wochenschr 1985;110:903-7.
4. Uzun O, Anaissie EJ. Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal. Blood 1995;86:2063-72.
5. Link H, Maschmeyer G, Meyer P, Hiddemann W, Stille W, Helmerking M, et al. Interventional antimicrobial therapy in febrile neutropenic patients. Study Group of the Paul Ehrlich Society for Chemotherapy. Ann Hematol 1994;69:231-43.
6. Ezdinli EZ, O'Sullivan DD, Wasser LP, Kim U, Stutzmann L. Oral amphotericin for candidiasis in patients with hematologic neoplasms. JAMA 1979;242:258-60.
7. Goa KL, Barradell LB. Fluconazole: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995;50:658-90.
8. Kern W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, et al. Superiority of high-dose over intermediate-dose cytosine arabinoside (AraC) in the treatment of patients with high-risk acute myeloid leukemia (AML). Ann Hematol 1997;74(2 Suppl 1):171.
9. Hiddemann W, Martin WR, Sauerland CM, Heinecke A, Büchner T. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment of thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia 1990;4:184-8.
10. Büchner T, Urbanitz D, Hiddemann W, Ruhl H, Ludwig WD, Fischer J, et al. Intensified induction and consolidation with or without maintenence chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985;3:1583-9.
11. Büchner T, Hiddemann W, Schaefer UW, Löffler H, Maschmeyer G, Ludwig WD, et al. Combined effect of very early intensification and prolonged post-remission chemotherapy in patients with AML. Leukemia 1992;6 (Suppl 4):68-70.
12. Kern W, Schleyer E, Unterhalt M, Wörmann B, Büchner T, Hiddemann W. High antileukemic activity of sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) in refractory acute leukemias: results of a clinical phase II study. Cancer 1997;79:59-68.
13. Hiddemann W, Martin WR, Sauerland CM, Heinecke A, Büchner T. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment of thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia 1990;4:184-8.
14. The Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient: report of a consensus panel. J Infect Dis 1990;161:397-401.
15. Behre GF, Schwartz S, Lenz K, Ludwig WD, Wandt H, Schilling E, et al. Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Ann Hematol 1995;71:287-91.
16. World Health Organization. A handbook for reporting results of cancer treatment. WHO Publication No. 38. Geneva: World Health Organization, 1979.
17. Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982;60:454-62.
18. Donelly JP, Starke ID, Galton DAG, Catovsky D, Goldman JM, Darrell JH. Oral ketoconazole and amphotericin B for the prevention of yeast colonisation in patients with acute leukemia. J Hosp Infect 1984;5:83-91.
19. Hann IM, Corringham R, Keaney M, Blacklock HA, Keaney M, Shannon M, et al. Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. Lancet 1982;333:826-9.
20. Palmblad J, Lönnqvist B, Carlsson B, Grimfors G, Jarnmark M, Lerner R, et al. Oral ketokonazole prophylaxis for candida infections during induction therapy for acute leukemia in adults: more bacteraemias. J Intern Med 1992;231:363-70.
21. Perfect JR, Klotman ME, Gilbert CC, Crawford DD, Rosner GL, Wright KA, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992;165:891-7.
22. Annaloro C, Oriana A, Tagliaferri E, Bertolli V, Della-Volpe A, Soligo D, et al. Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. Haematologica 1995;80:512-7.
23. Bodey GP, Anaissie EJ, Elting LS, Estey E, O'Brien S, Kantarjian H. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 1994;73:2099-106.
24. Egger T, Gratwohl A, Tichelli A, Uhr M, Stebler-Gysi C, Passweg J, et al. Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients: a prospective, randomized, single-center study. Support Care Cancer 1995;3:139-46.
25. Ellis ME, Clink H, Ernst P, Halim MA, Padmos A, Spence D, et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematologic malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1994;13:3-11.
26. Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, D'Antonio D, et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. The GIMEMA Infection Program. Ann Intern Med 1994;120:913-8.
27. Meunier F, Aoun M, Janssens M, Dekoster C, Paesmans M. Chemoprophylaxis of fungal infections in granulocytopenic patients using fluconazole vs. oral amphotericin B. Drug Invest 1991;3:258-65.
28. Ninane J and a multicenter study group. A multicenter study of fluconazole versus oral polyenes in the prevention of fungal infections in children with hematological or oncological malignancies. Eur J Clin Microbiol Infect Dis 1994;13:6-13.
29. Philpott-Howard JN, Wade JJ, Mufti GJ, Brammer KW, Ehninger G. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. J Antimicrob Chemother 1993;31:973-84.
30. Rozenberg-Arska M, Dekker AW, Branger J, Verhoef J. A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukemia. J Antimicrob Chemother 1991;27:369-76.
31. Bodey GP, Samonis G, Rolston K. Prophylaxis of candidiasis in cancer patients. Semin Oncol 1990;17 (Suppl 6):24-8.
32. Samonis G, Rolston K, Karl C, Miller P, Bodey GP. Prophylaxis of oropharyngeal candidiasis with fluconazole. Rev Infect Dis 1990;12:369-73.
33. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-52.
34. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
35. Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Ann Intern Med 1993;118:495-503.
36. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995;172:1035-41.
37. Chandrasekar PH, Gatney CM, Bone Marrow Transplantation Team. Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Chemotherapy 1994;40:136-43.
38. Maschmeyer G, Link H, Hiddemann W, Meyer P, Helmerking M, Eisenmann E, et al. Pulmonary infiltrations in febrile patients with neutropenia: risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. Cancer 1994;73:2296-304.
39. Link H, Hiddemann W, Maschmeyer G, Buchheidt D, Glass B, Cornely O, et al. Antimicrobial therapy in neutropenic patients with unexplained fever, PEG Study II. Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada. Washington, DC: ASM Press, 1997:372.
40. Johnson EM, Warnock DW. Azole drug resistance in yeasts. J Antimicrob Chemother 1995;36:751-5.
41. Nguyen MH, Peacock JE, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, et al. The changing face of candidemia: emergence of non-candida albicans species and antifungal resistance. Am J Med 1996;100:617-23.
42. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother 1994;38:1422-4.
43. Rex JH, Rinaldi MG, Pfaller MA. Resistance of candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1-8.
44. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993;37:1847-9.
45. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994;331:1325-30.
46. Anaissie EJ, Vartivarian SE, Abi-Said D, Uzun O, Pinczowski H, Kontoyiannis DP, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996;101:170-6.